Clint excels at handling complex legal problems with creativity and tact in situations where clients cannot afford to lose. A former federal prosecutor and member of the firm’s nationally ranked Government Investigations and White Collar Litigation Department, Clint represents companies and individuals in high-stakes white collar matters and strategically advises on U.S. Food and Drug Administration (FDA) legal, compliance, and policy issues.

Drawing on over a decade of prosecutorial experience, Clint represents clients in a wide range of investigations, enforcement actions, and criminal and civil litigation, including matters involving the Food, Drug, and Cosmetic Act (FDCA), the False Claims Act, healthcare fraud, financial fraud, research misconduct, unfair trade practices, and various consumer protection laws. His litigation work includes assisting clients with business disputes and navigating clients through parallel criminal, civil, and regulatory proceedings. Clint also provides expert advice on drug and device regulation across the product lifecycle, on topics ranging from clinical research and FDA application pathways to product manufacturing and postmarketing safety reporting. In addition, Clint counsels on food, dietary supplement, and tobacco product regulation, and advises on responding to FDA inspections and agency actions.

Before joining McGuireWoods, Clint served as an assistant director of the United States Department of Justice (DOJ) Consumer Protection Branch, where he led investigations and litigation involving pharmaceuticals and medical devices, clinical trial fraud, drug diversion, healthcare fraud, and other economic crimes. Before his tenure at the DOJ, Clint served in various capacities with the FDA’s Office of the Chief Counsel, where he supported the agency’s Health Care Fraud and Abuse Control (HCFAC) program and worked closely with the Center for Drug Evaluation and Research (CDER) and the Center for Devices and Radiological Health (CDRH). Clint also handled criminal jury trials and appeals while serving as a Special Assistant U.S. Attorney in multiple jurisdictions, and participated in research misconduct investigations involving the U.S. Department of Health and Human Services Office of Research Integrity.

Clint’s unique background enables him to provide insightful and nuanced advice to clients facing regulatory challenges. His proactive approach helps clients address potential issues before they escalate, ensuring compliance and minimizing risk. In situations where litigation becomes necessary, Clint tenaciously pursues his clients’ rights in courts.

Events

  • Panelist, "Updates in Advertising & Promotion, A Fireside Chat," Food and Drug Law Institute Advertising & Promotion for Medical Products Conference, October 15-16, 2025
  • Moderator, "FDA Enforcement," Healthcare Growth & Operations, September 16 - 17, 2025
  • Presenter, "Compliance Strategies for Decentralized Clinical Trials: A Former Regulator’s Perspective," Healthcare Compliance Association Research Compliance Conference, June 2-4, 2025
  • Panelist, "Regulatory Trends and Investment Opportunities in the Pharma Services Sector," 21st Annual Healthcare Private Equity and Finance Conference, May 14-15, 2025
  • Presenter, "Enforcement and Compliance in Clinical Research," Health Care Compliance Association 29th Annual Conference, May 1, 2025
  • Presenter, "What the DOJ and FDA are Looking for in Compliance Programs," Compliance Conversations by Healthicity, January 30, 2025
  • Moderator, "FDA and DOJ Clinical Trials Oversight – The Impact of Industry Modernization and Best Practices," Food and Drug Law Institute (FDLI), Enforcement, Litigation, and Compliance Conference, December 10, 2024
  • Presenter, "Research Fraud and Misconduct," Health Care Compliance Association (HCCA), Healthcare Enforcement Compliance Conference, November 20, 2024
  • Panelist, "Life Sciences Regulatory Essentials: What Investors Should Know," 17th Annual Healthcare Finance & Growth Conference, September 25 - 26, 2024
  • Presenter, "Enforcement Issues in Drug and Device Research," Health Care Compliance Association (HCCA), Research Compliance Conference, 2023
  • Presenter, "Enforcement in Research," HCCA, Healthcare Enforcement Compliance Conference, 2023
  • Presenter, "Clinical Trials: Deconstructing Challenges and Providing Practical Insights," Food and Drug Law Institute, 2022

Podcasts

  • Guest, "What Pharma Services Investors Should Know About Government Regulations, With Clint Narver," The Corner Series, November 25, 2024
  • Selected for inclusion in “Legal 500 United States,” Corporate Investigations and White-Collar Criminal Defense, 2025